Meeting report VLPNPV: Session 5: Plant based technology

Lydia R. Meador, Tsafrir Leket-Mor

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The VLPNPV 2014 Conference that was convened at the Salk institute was the second conference of its kind to focus on advances in production, puri fication, and delivery of virus-like particles (VLPs) and nanoparticles. Many exciting developments were reported and discussed in this interdisciplinary arena, but here we report specifically on the contributions of plant-based platforms to VLP vaccine technology as reported in the section of the conference devoted to the topic as well in additional presentations throughout the meeting. The increasing popularity of plant production platforms is due to their lower cost, scalability, and lack of contaminating animal pathogens seen with other systems. Reports include production of complex VLPs consisting of 4 proteins expressed at finely-tuned expression levels, a prime-boost strategy for HIV vaccination using plant-made VLPs and a live viral vector, and the characterization and development of plant viral nanoparticles for use in cancer vaccines, drug delivery, and bioimaging.

Original languageEnglish (US)
Pages (from-to)3068-3073
Number of pages6
JournalHuman Vaccines and Immunotherapeutics
Issue number10
StatePublished - Oct 1 2014


  • Bluetongue virus
  • C-Erbb-2 (human epidermal growth factor receptor 2)
  • Cowpea mosaic virus
  • HIV-1
  • Hepatitis b core antigen
  • Live viral vectors
  • Potato virus x
  • Tobacco mosaic virus
  • Viral nanoparticles
  • Virus-like particles

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Meeting report VLPNPV: Session 5: Plant based technology'. Together they form a unique fingerprint.

Cite this